Structure Therapeutics (GPCR) vs Precigen (PGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Precigen (PGEN) has outperformed Structure Therapeutics (GPCR) over the past year, gaining 136.0% versus a loss of 9.8%. Precigen is the larger company by market cap ($2.72 billion vs $1.83 billion), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GPCR | PGEN |
|---|---|---|
| Share price | $25.67 | $7.60 |
| Market cap | $1.83B | $2.72B |
| 1-day change | -3.79% | +0.80% |
| YTD return | -63.09% | +81.82% |
| 1-year return | -9.77% | +136.02% |
| 5-year return | — | +63.44% |
| EPS (TTM) | $-3.03 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $9.68M |
| Revenue growth (YoY) | — | +146.73% |
| Net income (latest FY) | — | $-250.64M |
| Operating margin | — | -1141.13% |
| Net margin | — | -2588.21% |
| 52-week high | $94.90 | $8.98 |
| 52-week low | $25.09 | $2.99 |
| Distance from 52-week high | -72.95% | -15.37% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +312.08% | +79.61% |
| Average volume | 965.00K | 5.03M |
| Shares outstanding | 71.31M | 358.04M |
| Employees | 281 | 160 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PGEN has outperformed GPCR by 145.8 percentage points over the past year.
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Healthcare · Biotechnology · 281 employees
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Healthcare · Biotechnology · 160 employees
GPCR vs PGEN FAQ
Which is bigger, Structure Therapeutics or Precigen?
Precigen (PGEN) is larger, with a market capitalization of $2.72B compared with $1.83B for Structure Therapeutics (GPCR).
Which stock has performed better over the past year, GPCR or PGEN?
PGEN returned +136.02% over the past 12 months, compared with -9.77% for GPCR (price return, excluding dividends). Past performance does not predict future results.
Are Structure Therapeutics and Precigen in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.